NEW HAVEN, Conn., Oct. 22, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biotechnology company focused on advancing innovative therapies for neurological diseases, today announced that the first participant was dosed with BHV-3500, a third generation...